Non-Current Assets
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments
Boston Scientific Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments increased by 38.5% to $396M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.3%, from $297M to $396M. Over 5 years (FY 2020 to FY 2025), Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments shows an upward trend with a 9.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2017
Last reportedQ1 2026May 1, 2026
Metric ID:
equity_securities_no_fv_downward_adjHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $175M | $164M | $142M | $165M | $159M | $171M | $219M | $219M | $215M | $207M | $194M | $218M | $243M | $276M | $277M | $297M | $292M | $310M | $286M | $396M |
| QoQ Change | — | -6.3% | -13.4% | +16.2% | -3.6% | +7.5% | +28.1% | +0.0% | -1.8% | -3.7% | -6.3% | +12.4% | +11.5% | +13.6% | +0.4% | +7.2% | -1.7% | +6.2% | -7.7% | +38.5% |
| YoY Change | — | — | — | — | -9.1% | +4.3% | +54.2% | +32.7% | +35.2% | +21.1% | -11.4% | -0.5% | +13.0% | +33.3% | +42.8% | +36.2% | +20.2% | +12.3% | +3.2% | +33.3% |
Range$142M – $396M
CAGR+18.8%
Avg YoY Growth+20.1%
Median YoY Growth+20.6%
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at Other Companies
Frequently Asked Questions
- What is Boston Scientific's equity securities without readily determinable fair value - cumulative downward adjustments?
- Boston Scientific (BSX) reported equity securities without readily determinable fair value - cumulative downward adjustments of $396M in Q1 2026.
- How has Boston Scientific's equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?
- Boston Scientific's equity securities without readily determinable fair value - cumulative downward adjustments increased by 33.3% year-over-year, from $297M to $396M.
- What is the long-term trend for Boston Scientific's equity securities without readily determinable fair value - cumulative downward adjustments?
- Over 5 years (2020 to 2025), Boston Scientific's equity securities without readily determinable fair value - cumulative downward adjustments has grown at a 9.3% compound annual growth rate (CAGR), from $183M to $286M.